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Abstract
From research to application, high protein solubility is usually a desired property yet sometimes difficult to 
achieve. The in vitro low solubility of the fully folded proteins is relevant to applied microbiological studies, 
biochemical studies, biopharmaceutical studies, high-resolution structural studies, and applications demanding 
high protein concentration. This insufficient protein solubility depends largely on the surface property of the 
protein molecule. To alleviate this problem, approaches emphasized on the improvement of water-binding 
ability or prevention of protein aggregation were employed including the use of chemical additives, fusion 
with solubility enhancement tags, and molecular engineering of the surface amino acid residues. With the 
availability of the three-dimensional structure of the target proteins, the effect of different surface amino 
acid residues on protein solubility could be systematically investigated. With the applications of advanced 
bioinformatics tools and guided by protein three-dimensional structure, solubility-improving mutagenesis 
can be designed and executed with a high chance of success. Integrating rational molecular engineering with 
other available approaches will be the effective strategy for alleviating in vitro low solubility of important 
proteins in the future.
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1 Introduction
Protein engineering has been developed for more than 
half a century and still plays increasingly significance 
roles in several fields, particularly applied microbiology, 
biochemistry, biotechnology, and biopharmaceutical 
applications of proteins and enzymes. High kinetic 
activity, high protein solubility, and long-term stability 
are properties generally required in research and 
applications. Investigations on improving of kinetic 
activity and stability have been the topics of active 
research, but study for increasing protein solubility 
receives less attention. Cumulative documents 
reveal that up to 80% of the identified non-membrane 
proteins are low protein solubility [1-3]. This problem 
often obstructs the preparation of concentrated 
protein for high-resolution structural determination, 
quantitative binding assays, and characterization 
of the novel proteins. Likewise, more than 90% 
of all pharmaceutical proteins are unsuitable for 
pre-clinical study because of their low solubility [4]. 
It is evident that low protein solubility is one of the main 
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bottlenecks in protein technology, which can happen 
during production, purification, preparation, shipping, 
storage, and downstream application steps. Various 
techniques for increasing protein solubility have been 
developed. Solubility of purified protein could be 
improved by dissolving in optimized buffer formulated 
with selected salts and additives [5]. Genetic fusion 
with short peptide (solubility enhancement tag) is 
an easy and commercially available method for 
improvement of protein solubility. Recently, rational 
mutagenesis of surface amino acid residues to enhance 
protein solubility has been developed [6,7]. Beside 
those experimental techniques, bioinformatics tools 
for molecular modeling and predicting protein 
solubility from the amino acid sequence or three-
dimensional structure [8,9] contribute significantly 
to the success in solubility-enhancing protein 
engineering. In this review, the definition of low 
protein solubility and the strategies for alleviating 
in vitro low protein solubility, especially the novel 
approaches are discussed.
2 Definition and Background of Protein Solubility
Thermodynamically, solubility is the relation between 
the nature of the solute and the solvent defined as an 
amount of a substance (a solute) that can be totally 
dissolved in a given amount of a solvent. Accordingly, 
protein solubility is defined as an amount of protein 
that can be completely dissolved in the water or buffer 
under the given environmental conditions and solution 
components. In biochemical and pharmaceutical study 
of proteins, the equilibrium solubility which is the 
concentration of a solute in its saturated solution exists 
in a state of equilibrium with pure solid solute is usually 
considered [10]. The concentration of the solute in the 
solution is constant as long as the environment factors 
and solution components are maintained. In practice, 
protein solubility is determined from the concentration 
of soluble protein in equilibrium with the solid phase 
under given conditions of pH, temperature, buffer 
concentration, and additives [11]. If the concentration 
of a protein exceeds its equilibrium solubility limit, 
the solution becomes supersaturated and protein in 
the solution moves to the insoluble phase either as an 
amorphous precipitation (disordered aggregation) or 
as a microcrystalline form [12] until a new solution 
equilibrium is established.
 Protein solubility is a complex phenomenon 
affected by multiple intertwined factors and remains 
to be fully understood [13]. Factors influencing 
protein solubility can be classified into two groups, the 
extrinsic and intrinsic factors. Extrinsic or environment 
factors include conditions of pH, temperature, ionic 
strength, ionic composition, and solution composition. 
The pH of the solution is generally considered as 
the important extrinsic factor that influences protein 
solubility [14]. The intrinsic factor corresponds with 
the pH effect of the solution is the isoelectric point (pI) 
of the protein. The pI is the pH at which the protein 
has a net charge of zero or the balance of positive and 
negative charges. Protein solubility reaches a minimum 
when the pH of the environment is equal to the pI. 
Moving away from the pI value, either to the higher 
or lower pH, usually increases the protein solubility. 
Thus, knowing the pI of a protein is crucial for 
manipulating its solubility. Intrinsic properties of a 
protein are governed by the amino acid sequence that 
determines the folding process, the conformational 
structure, the solvent accessible surface area, and the 
net charge of the protein, all of which can affect protein 
solubility.
3 Classification of Low Protein Solubility
There are several types of low protein solubility 
reported in the literature, but the classification 
has been ambiguous and confusing [11]. Up to 
the present, the most useful low protein solubility 
classification is that proposed by Trevino [11] which 
discriminates low protein solubility into four types 
based on pharmaceutical applications. These are 
(i) low in vitro solubility, (ii) low in vivo solubility, 
(iii) amyloid formation, and (iv) low protein solubility 
due to conformational changes. In the present review, 
however, the classification of low protein solubility 
is re-organized into only two types which are 
(i) the in vivo low protein solubility caused by 
the failure to reach the fully folded state during 
expression in the host cell and (ii) the in vitro low 
solubility of the fully folded proteins after isolation 
from the host cell. The advantage of this new 
classification is to prevent the confusion in terms of 
the definition and the determination of strategies for 
improving protein solubility relevant to biotechnology 
and microbiology.
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3.1  In vivo low protein solubility
Cytoplasmic and periplasmic inclusion body (IB) 
formation is a common problem of high-level 
expression of heterologous proteins in Escherichia coli. 
Generally, the over-expressed level of the heterologous 
proteins, the hydrophobic characteristic of the proteins, 
insufficient number of molecular chaperones, and the 
reducing condition in the cytoplasm of E. coli are the 
major causes of imperfect folding or misfolding of the 
proteins. When the proteins unfold or incorrectly fold, 
hydrophobic amino acid residues (Ala, Val, Ile, Leu, 
Met, Phe, Trp, and Cys) which are normally buried in 
the folded state become exposed [15]. The contacts 
between nonspecific regions intra- or inter-molecularly 
lead to amorphous (disordered) aggregations through 
non-covalent hydrophobic or ionic interactions or the 
combination of both [16] forming inclusion bodies. 
The inclusion bodies are dynamic structures formed 
by an unbalanced equilibrium between aggregated 
(solid phase) and soluble proteins in the expressing 
host cell [17]. In the review by Trevino [11], this low 
protein solubility type was classified in the group of 
low in vivo solubility. 
 Evidence suggested an association between 
inclusion body and the conformational instability 
of protein folding process. Using statistical analysis 
of the amino acid compositions of 81 proteins, it 
was reported that proteins in their partially unfolded 
conformation especially at early intermediate stage 
could generate insoluble inclusion body [18]. Based on 
mutational analysis, it was proposed that the success of 
the folding process of a protein depends on it having 
sufficient conformational stability [19].
3.2  In vitro low protein solubility
Another type of solubility problem addressed in this 
review is low solubility of the fully folded protein 
(or low in vitro solubility). In this case, the proteins 
can be expressed, folded properly, and can be purified 
in their native form, but cannot be concentrated 
sufficiently for further applications such as biochemical 
studies and pharmaceutical use. Protein aggregation 
or precipitation is driven mainly by surface interaction 
of the folded state. It is different from the aggregation 
of partially or fully unfolded protein that is caused 
by the exposed hydrophobic cores. Proteins at the 
concentrations of several mg/mL are usually required 
for structural analyses such as X-ray crystallography 
and nuclear magnetic resonance technique. Therapeutic 
monoclonal antibodies need to be prepared at more 
than one hundred mg/mL in a small volume [6] for 
subcutaneous administration [20]. High protein 
concentration is difficult to achieve for most expressed 
proteins because they have limited solubility and 
propensity to aggregate or precipitate. Under any 
particular controlled extrinsic conditions, key intrinsic 
determinants for precipitation of the fully folded 
proteins include net charge, hydrophobicity, size, and 
conformation of the proteins. 
 The amino acid residues whose side chain are 
exposed on the surface of the folded protein molecule 
contribute to the net charge and hydrophobicity which 
are the two major intrinsic factors that determine 
solubility of the protein. The effect of net charge on protein 
solubility at the controlled pH was systematically 
analyzed using the wild-type and mutants of ribonuclease 
Sa (RNase Sa) [21]. The results confirmed that the 
net charge of a protein depends on the content of 
ionizable groups and pKa values of the surface amino 
acid residues. High net charge and number of surface 
ionizable residues contributes favorably to solubility 
of the RNase Sa. 
 When dissolving solid protein in an aqueous 
buffer solution, solubility is also influenced by the 
form of the solid phase in equilibrium with the solution 
phase. In the amorphous solid form the protein molecules 
arrange randomly and loosely. In contrast, in the 
crystalline solid form the protein molecules arrange 
orderly and more tightly. Generally, solubility of protein 
in an amorphous form is higher than when it is in the 
crystalline form. 
4 Strategies for Increasing in vitro Protein Solubility
The problem of in vivo low protein solubility associates 
mainly with protein folding process in the host cell 
during and after translation. Strategies for solving 
this problem emphasize how to improve yield of the 
correctly folded proteins. Several approaches have 
been employed and reviewed elsewhere, for instance, 
the development of different E. coli host strains, 
optimization of culture conditions, addition of chemical 
chaperones, and co-expression of molecular chaperones 
[22]. Molecular engineering of the target proteins can 
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be done to improve their solubility provided that the 
modifications do not affect their intended use. These 
include fusion with solubility enhancing peptide tag 
and protein modification by structure-guided directed 
mutagenesis.
 For in vitro low protein solubility, the proteins 
can be successfully over-expressed and purified but 
cannot be concentrated sufficiently for their intended 
use such as for high-resolution structural studies and 
biopharmaceutical applications. To solve this problem, 
optimizations of extrinsic (environmental) factors and 
intrinsic factors (modification of the protein itself) 
have been developed.
4.1  Use of chemical additives
The in vitro solubility of fully folded proteins can be 
increased by supplementing some additives to the 
buffers during purification, concentration, and storage. 
The commonly used chemical additives for this 
purpose are detergents, sugars, and salts. Chloride 
salts at concentrations below 1 M have been used 
as the agent for improving protein solubility by the 
phenomenon known as salting-in effect. 
 Apart from the commonly used additives such as 
sodium chloride, sucrose, and sorbitol, the addition of 
charged L-amino acids has been used for improving 
solubility of protein. Simultaneous addition of 50 mM 
L-arginine and L-glutamate to the buffer can 
significantly increase (up to 8.7 times) the solubility 
of several unrelated recombinant proteins with known 
solubility problems. With these amino acid additives, 
in vitro protein aggregation and precipitation were 
effectively prevented, long-term storage stability was 
dramatically increased, and the protein samples were 
protected from proteolytic degradation [23]. Arginine 
alone could suppress protein aggregation and protein-
protein or protein-surface interaction during protein 
purification and in vitro protein re-folding process. 
L-Arg and L-Glu have been used as the excipients 
for helping the solubility of pharmaceutical proteins 
and peptides [24]. The solubility of fibroblast growth 
factor 20 (FGF-20) increased with the increasing 
concentration of arginine-sulfate in a low range but a 
salting out effect was observed at high arginine-sulfate 
concentration range [25]. The added L-Arg and L-Glu 
did not interfere with downstream processes such as 
SDS-PAGE analysis, solution-state studies by NMR, 
specific protein-protein interactions, and protein-RNA 
interactions. However, the presence of L-Arg and 
L-Glu in the solution does interfere with protein 
binding to the ion-exchange columns used for the 
protein purification.
4.2  Fusion with solubility tags
For in vitro solubility enhancement, usually the tag 
should remain with the target protein after expression, 
purification, and throughout the application. The first 
example is the non-cleavage solubility-enhancement 
tag (SET) derived from the highly stable and highly 
soluble 56-aa peptide of the B1 domain of protein G 
[26]. Fusion of this tag to the N-terminus of target 
proteins could significantly improve both solubility 
and stability of the heterodimeric complex between 
regulatory domains of human DNA fragmentation 
factor 40 (DFF40) and human DNA fragmentation 
factor 45 (DFF45) CIDE domains. The second example 
is the tag derived from the novel stabilizing peptide 
acidic tail of synuclein (ATS) [27]. By fusion to 
the C-terminus of human growth hormone (hGH), 
granulocyte colony-stimulating factor (G-CSF), and 
human leptin; the ATS was found to greatly increase 
the solubility, the storage stability and resistance to 
environmental stresses such as agitation and freeze/thaw 
of the fusion proteins. Alternatively, the highly 
positively-charged solubility enhancement peptide 
(SEP) tags containing short poly-Lys or poly-Arg 
were developed [13]. The SEP tags could increase 
the solubility of a bovine pancreatic trypsin inhibitor 
(BPTI) variant in a direct relation to the number of 
positively-charged residues of the tag. Recently, the 
same research group measured the effects of 10 short 
poly-amino-acid tags on the solubility of BPTI and 
determined the positively-charged or negatively-charged 
tags affected BPTI solubility under a close to neutral 
pH condition (pH 7.7) [28]. These tags did not alter the 
conformational structure, thermal stability or activity 
of fusion partner. 
4.3  Molecular modifications by directed mutagenesis
Several studies have succeeded in improving the 
protein solubility of fully folded proteins by using 
site-directed mutagenesis as reviewed in Trevino et al 
[11]. This approach can be more useful in several target 
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proteins when compared to the fusion with solubility 
enhancement tag. Importantly, this approach does 
not significantly change the molecular weight of the 
target protein and does not affect the high-resolution 
structural studies. Principally, solubility enhancement 
mutagenesis is done by replacing the hydrophobic 
surface amino acid residues with charged, polar, 
hydrophilic [29] or less hydrophobic residues. The 
surface charged or polar amino acids enhance the 
protein-water interaction resulting in improvement of 
protein solubility, whereas the hydrophobic residues 
promote hydrophobic interaction between protein 
molecules that leads to protein aggregation. The 
naturally occurring F185K mutant type of HIV-1 
integrase catalytic domain (INC) was found to have 
dramatically increased solubility. Structural analysis 
revealed that this mutation altered the salt bridge 
network that drove the conformational change of 
INC in such a way that some hydrophobic residues 
were buried while some other hydrophilic residues 
were exposed on the protein surface. With more 
hydrophilic and less hydrophobic surface residues, the 
protein-water was enhanced and this contributed to 
the solubility increase of INC [30]. Correspondingly, 
the structured-based engineering of the anti-IL-13 
monoclonal antibody CNTO607 showed significantly 
more solubility when replacing an aggregation hot spot 
or surface hydrophobic patch containing three residues 
(F99-H100-W100a) in heavy-chain CDR3 to triple 
alanine residues [31].
 Recently a systematic study to compare the 
contribution of all 20 amino acids to protein solubility 
using RNase Sa, which is a small enzyme with 96 
amino acids residues and one disulfide bond, as a 
model. A completely solvent exposed position, Thr76, 
was chosen as the position for mutation by replacing 
it with the other 19 amino acids, and the solubility of 
each mutant was measured. The results showed that 
the acidic amino acids (Asp and, Glu) contributed 
significantly more favorably than any other hydrophilic 
amino acids including Arg, Lys, Asn, Gln, and Thr 
under both low and high net charge conditions [6,11,29]. 
This is supported by the solubility measurement 
study of seven proteins in ammonium sulfate and 
polyethyleneglycol 8000. It found that increased 
negative surface charge of the proteins had a positive 
effect on in vitro solubility [14] due to the strong 
water-binding properties of the acidic amino acids 
[32]. This finding provides valuable insight for the 
understanding of protein solubility and it was applied 
to a larger and unrelated protein D-phenylglycine 
aminotransferase (D-PhgAT), a homo-dimeric 
enzyme consisted of two identical 47-kDa subunits from 
Pseudomonas stutzeri. Double point mutations to 
change the highly solvent-exposed residue at position 
N439 and Q444 involved with protein crystal-packing 
contacts to the acidic amino acids resulted in a mutant 
enzyme having 5.9 times greater  solubility [7], 
confirming the reliability of the approach. 
 The finding that acidic amino acids contribute 
most favorably to protein solubility is in good 
agreement with the effect of the acidic solubility tag or 
negatively-charged tag mentioned above as well as the 
high prevalence of acidic amino acids on the surface 
of proteins from halophiles which would make the 
protein soluble in an environment of reduced water 
activity [33].
 With current knowledge, rationale molecular 
engineering to improve protein solubility can be done 
with a higher chance of success than before. However, 
the ability to precisely identify the surface residue 
candidate for mutation will rely on the availability of 
the good three-dimensional structure of the candidate 
protein.
5 Future Prospects
The use of fusion tags will be more popular due to 
their effectiveness and versatility. Further development 
should be focused on the creation of multifunctional 
tags that can serve many purposes. In addition to 
enhancing solubility of the target protein, the tag can be 
designed to be able to enhance protein expression at the 
transcription-translation level, assist in protein folding, 
stabilization of the partner protein, simplify protein 
purification and tag removal. The new tags should be 
smaller in size so that they will not pose much burden 
on the resources of the host cells, but equally or more 
effective than the previous tags. Solubility and stability 
enhancing molecular engineering of proteins will 
gain more attention and utilization since the success 
of the rationale mutations is evident. This can be an 
effective approach provided that the mutations do not 
affect the final application of the proteins, especially in 
therapeutic use. The only bottleneck to this approach 
is the limited availability of the three-dimensional 
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structure of the target proteins for guiding the precise 
mutation scheme.
 The final goal is not to develop a single best 
method to solve the protein insolubility problem. 
Rather, a combination of carefully selected approaches 
will be the only way to maximize the target protein 
production. This should be optimized on a case by case 
basis using all the available options. 
6 Conclusions
Large amounts of proteins and enzymes are continually 
required for processes and applications in several 
industrial sectors, agriculture, consumer markets, 
pharmaceutical, and therapeutic use etc. In order to 
generate good supply of proteins and enzymes to 
meet these high demands with economically viable 
production cost, effective expression systems are 
of the prime importance. For proteins that can be 
expressed successfully, some may face the problem of 
in vitro low protein solubility, which can obstruct their 
further development that requires the protein in high 
concentrations. Enhancement of the in vitro protein 
solubility can be achieved by using chemical additives 
such as sugars or certain amino acids, fusion with a 
solubility tag that may remain with the protein until 
the final use and solubility enhancing mutagenesis. 
In alleviating the protein insolubility, the cause of the 
problem should be indentified and the methods for 
improving protein solubility should be carefully 
selected. Usually, the best result will be obtained from 
the proper combination of many methods. Thus, all the 
available old and new methods should be studied in 
details in order to formulate an effective operational 
approach.
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